Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.

BACKGROUND It has been proposed that subtype-related human immunodeficiency virus type 1 (HIV-1) variability may influence virologic and immunologic responses to highly active antiretroviral therapy (HAART). Studies to date, however, have described treatment outcomes predominantly in persons with subtype B infection or compared subtype B with diverse non-B subtypes grouped together. METHODS With use of data from the linked UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study databases, time to viral load undetectability (viral load, <50 copies/mL), time to virologic rebound (viral load, >1000 copies/mL), and increases in the CD4 cell count were compared for a median of 39 months (interquartile range, 23-67 months) in drug-naive patients infected with subtype B (n=1550), subtype C (n=272), subtype A (n=66), circulating recombinant form AG (n=57), or subtype D (n=41) disease who started HAART. RESULTS Overall, 1906 (90%) of 2116 patients achieved viral load undetectability within 12 months after they started HAART, of whom 335 (18%) subsequently experienced virologic rebound. In adjusted analyses, viral load suppression occurred more rapidly in patients infected with subtype C (hazard ratio, 1.16; 95% confidence interval, 1.01-1.33; P=.04) and subtype A (hazard ratio, 1.35; 95% confidence interval, 1.04-1.74; P=.02) relative to subtype B infection. The virologic rebound occurred marginally more rapidly in patients with subtype C infection (hazard ratio, 1.40; 95% confidence interval, 1.00-1.95; P=.05), but the hazard of virologic rebound was similar with other subtypes. Although persons with subtype B infection showed higher baseline CD4 cell counts and maintained the advantage throughout therapy, CD4 cell count recovery occurred at similar rates with all subtypes. CONCLUSIONS Patients infected with prevalent non-B subtypes were as likely to achieve viral load suppression as persons infected with subtype B and showed comparable rates of CD4 cell count recovery. HAART achieves excellent outcomes regardless of the infecting subtype.

[1]  A. Tanuri,et al.  Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. , 2005, The Journal of infectious diseases.

[2]  Alessandro Cozzi-Lepri,et al.  Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. , 2004, The Journal of infectious diseases.

[3]  J. Benito,et al.  Impact of ethnicity and HIV type 1 subtype on response to first-line antiretroviral therapy. , 2007, AIDS research and human retroviruses.

[4]  Oliver Laeyendecker,et al.  Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. , 2008, The Journal of infectious diseases.

[5]  B. Masquelier,et al.  Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data. , 2006, AIDS research and human retroviruses.

[6]  F. Mazzotta,et al.  HIV‐1 subtypes and circulating recombinant forms (CRFs) from HIV‐infected patients residing in two regions of central and southern Italy , 2005, Journal of medical virology.

[7]  R. Detels,et al.  Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study* , 2004, AIDS.

[8]  Kholoud Porter,et al.  The creation of a large UK‐based multicentre cohort of HIV‐infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study , 2004, HIV medicine.

[9]  D. Kuritzkes,et al.  Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy: Results of ACTG A5095 , 2007, Journal of acquired immune deficiency syndromes.

[10]  H. Goldstein.  Multilevel Statistical Models , 2006 .

[11]  A. Mocroft,et al.  HIV-1 Subtypes and Response to Combination Antiretroviral Therapy in Europe , 2006, Antiviral therapy.

[12]  R. Kantor.  Impact of HIV-1 pol diversity on drug resistance and its clinical implications , 2006, Current opinion in infectious diseases.

[13]  Lynn Morris,et al.  Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration , 2005, PLoS medicine.

[14]  P. Easterbrook,et al.  Evidence for Onward Transmission of HIV-1 Non-B Subtype Strains in the United Kingdom , 2006, Journal of acquired immune deficiency syndromes.

[15]  F. Brun-Vézinet,et al.  French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002 , 2005, Journal of acquired immune deficiency syndromes.

[16]  A. Phillips,et al.  Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.

[17]  D. Pillay,et al.  Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study , 2005, BMJ : British Medical Journal.

[18]  F. Granath,et al.  Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy. , 2005, AIDS research and human retroviruses.

[19]  Dorothy M. Lang,et al.  Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels , 2005, Journal of Virology.

[20]  Anne-Mieke Vandamme,et al.  Investigation of Baseline Susceptibility to Protease Inhibitors in HIV-1 Subtypes C, F, G and Crf02_Ag , 2005, Antiviral therapy.

[21]  F. Antunes,et al.  Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. , 2008, The Journal of antimicrobial chemotherapy.

[22]  K. Ariyoshi,et al.  Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy , 2002, AIDS.

[23]  A. Geretti,et al.  HIV-1 subtypes: epidemiology and significance for HIV management , 2006, Current opinion in infectious diseases.

[24]  E. Arts,et al.  Differences in the Fitness of Two Diverse Wild-Type Human Immunodeficiency Virus Type 1 Isolates Are Related to the Efficiency of Cell Binding and Entry , 2005, Journal of Virology.

[25]  M. Hoelscher,et al.  HIV-1 diversity and prevalence differ between urban and rural areas in the Mbeya region of Tanzania , 2005, AIDS.

[26]  B. Gazzard,et al.  The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. , 2005, The Journal of infectious diseases.

[27]  Á. Holguín,et al.  Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. , 2006, AIDS reviews.

[28]  B. Gazzard,et al.  Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures , 2007, AIDS.

[29]  J. Margolick,et al.  Interruption and Discontinuation of Highly Active Antiretroviral Therapy in the Multicenter AIDS Cohort Study , 2005, Journal of acquired immune deficiency syndromes.

[30]  Y. Yazdanpanah,et al.  Impact of Human Immunodeficiency Virus Type 1 Subtype on First-Line Antiretroviral Therapy Effectiveness , 2005, Antiviral therapy.

[31]  M. Peeters,et al.  Impact of HIV-1 Genetic Diversity on Plasma HIV-1 RNA Quantification: Usefulness of the Agence Nationale de Recherches sur le SIDA Second-Generation Long Terminal Repeat-Based Real-Time Reverse Transcriptase Polymerase Chain Reaction Test , 2007, Journal of acquired immune deficiency syndromes.

[32]  T. Sata,et al.  HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  P. Harrigan,et al.  Prevalence and Response to Antiretroviral Therapy of Non-B Subtypes of HIV in Antiretroviral-Naive Individuals in British Columbia , 2002, Antiviral therapy.

[34]  B. Gazzard,et al.  Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study , 2005, BMJ : British Medical Journal.

[35]  F. Wit,et al.  Virologic and Immunologic Response to Highly Active Antiretroviral Therapy in Indigenous and Nonindigenous HIV-1–Infected Patients in The Netherlands , 2004, Journal of acquired immune deficiency syndromes.

[36]  U. Lalloo,et al.  Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8. , 2005, The Journal of infectious diseases.

[37]  N. Clumeck,et al.  Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients , 2004, AIDS.